Literature DB >> 21508295

Higher Risk of Severe Drug-Induced Liver Injury among Hispanic HIV-Infected Patients after Initiation of Highly Active Antiretroviral Therapy.

Zanetta S Lamar1, Marina Núnez.   

Abstract

BACKGROUND: Little is known about differences across ethnicities in the development of drug-induced liver injury (DILI) after highly active antiretroviral therapy (HAART) initiation.
METHODS: This is a retrospective, longitudinal, comparative, pilot study. DILI within the first year of HAART was evaluated in 50 HIV-infected Hispanics without viral hepatitis who initiated HAART between 2000 and 2009. It was compared to white and black patients (1:1:1) matched by age and CD4 counts.
RESULTS: HAART-related DILI of any grade occurred in 30 of 150 (20%) patients and was associated with nonnucleoside reverse transcriptase inhibitor (NNRTI) use (OR 4.49 [95%CI 1.5-13.8]). Severe DILI was significantly more frequent among Hispanics compared to other groups (6% vs. 0%; P = .04). Of the 3 patients with severe DILI, 2 underwent liver imaging and had hepatic steatosis.
CONCLUSIONS: Severe DILI within the first year of HAART initiation was infrequent and restricted to Hispanics. Additional studies are needed to determine if fatty liver is involved in the excess of severe DILI observed in this group.

Entities:  

Mesh:

Year:  2011        PMID: 21508295     DOI: 10.1177/1545109711401411

Source DB:  PubMed          Journal:  J Int Assoc Physicians AIDS Care (Chic)        ISSN: 1545-1097


  6 in total

1.  Antitubercular therapy induced liver function tests abnormalities in human immunodeficiency virus infected individuals.

Authors:  Pankaj Puri; Navjyot Kaur; Sunny Pathania; Sandeep Kumar; P K Sharma; V K Sashindran
Journal:  Med J Armed Forces India       Date:  2017-01-07

2.  Genome-Wide Association and Replication Study of Hepatotoxicity Induced by Antiretrovirals Alone or with Concomitant Anti-Tuberculosis Drugs.

Authors:  Zelalem Petros; Ming Ta Michael Lee; Atsushi Takahashi; Yanfei Zhang; Getnet Yimer; Abiy Habtewold; Ina Schuppe-Koistinen; Taisei Mushiroda; Eyasu Makonnen; Michiaki Kubo; Eleni Aklillu
Journal:  OMICS       Date:  2017-04

3.  Liver enzyme abnormalities and associated risk factors in HIV patients on efavirenz-based HAART with or without tuberculosis co-infection in Tanzania.

Authors:  Sabina Mugusi; Eliford Ngaimisi; Mohamed Janabi; Omary Minzi; Muhammad Bakari; Klaus-Dieter Riedel; Juergen Burhenne; Lars Lindquist; Ferdinand Mugusi; Eric Sandstrom; Eleni Aklillu
Journal:  PLoS One       Date:  2012-07-11       Impact factor: 3.240

4.  Evaluation of patterns of liver toxicity in patients on antiretroviral and anti-tuberculosis drugs: a prospective four arm observational study in ethiopian patients.

Authors:  Getnet Yimer; Marcus Gry; Wondwossen Amogne; Eyasu Makonnen; Abiy Habtewold; Zelalem Petros; Getachew Aderaye; Ina Schuppe-Koistinen; Lars Lindquist; Eleni Aklillu
Journal:  PLoS One       Date:  2014-04-08       Impact factor: 3.240

Review 5.  Mechanistic insights into antiretroviral drug-induced liver injury.

Authors:  Jamie N Pillaye; Mohlopheni J Marakalala; Nonhlanhla Khumalo; Wendy Spearman; Hlumani Ndlovu
Journal:  Pharmacol Res Perspect       Date:  2020-08

Review 6.  Liver involvement in human immunodeficiency virus infection.

Authors:  Pankaj Puri; Sandeep Kumar
Journal:  Indian J Gastroenterol       Date:  2016-06-03
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.